DCPH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.08% compare to its pairs and should correct upwards.

Stats
Dzisiejszy wolumen	1.57M
Średni wolumen	2.04M
Kapitalizacja rynkowa	2.21B
EPS	$-0.520 ( Q1 \| 2024-05-10 )
Następna data zysków	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.58 (Sector) 42.63 (Industry) 0
ATR14	$0.00600 (0.02%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Brightstar Associates Llc	Buy	48 136	Common Stock
2024-04-22	Brightstar Associates Llc	Sell	48 136	Warrants (right to buy)
2024-02-15	Sherman Matthew L	Buy	17 275	Common Stock
2024-02-16	Sherman Matthew L	Sell	2 615	Common Stock
2024-02-15	Sherman Matthew L	Buy	69 100	Stock Option (Right to Buy)

INSIDER POWER
30.99
Last 99 transactions
Buy: 7 012 970 \| Sell: 3 558 980

Korelacja (AI algo v.1.1b): Undervalued: 0.08% $25.63 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.56 (weak)

Krótki: 0.95 (very strong)

Signal:(68.551) Expect same movement, but be aware

Deciphera Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
OZEM	1
AGBA	0.95
THCP	0.909
POET	0.893
NTIC	0.888
HIBB	0.874
UAL	0.872
STCN	0.869
NBBK	0.868
HLP	0.857

10 Najbardziej negatywne korelacje
RFAIU	-0.958
ICLK	-0.943
INDH	-0.921
VAXX	-0.9
IIMFX	-0.876
CETX	-0.869
ERNZ	-0.856
IBAC	-0.855
GLYC	-0.85
GRDI	-0.848

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Deciphera Pharmaceuticals Korelacja - Waluta/Towar

0.02
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.30
( neutral )

Deciphera Pharmaceuticals Finanse

Annual	2023
Przychody:	$163.36M
Zysk brutto:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2023
Przychody:	$163.36M
Zysk brutto:	$159.62M (97.72 %)
EPS:	$-2.29

FY	2022
Przychody:	$134.04M
Zysk brutto:	$125.27M (93.46 %)
EPS:	$-2.37

FY	2021
Przychody:	$96.15M
Zysk brutto:	$93.22M (96.95 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Deciphera Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.